APREEarnings•globenewswire•
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
Sentiment:Negative (30)
Summary
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire